Henan Taloph Pharmaceutical Stock Co Ltd (600222) — Strategic Asset Allocation Index
Henan Taloph Pharmaceutical Stock Co Ltd (600222) has a Strategic Asset Allocation Index of 33.5% as of September 2022. Strategic assets (PP&E of CN¥538.86 Million plus long-term investments of CN¥-) total CN¥538.86 Million, measured against net assets of CN¥1.61 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Henan Taloph Pharmaceutical Stock Co Ltd Strategic Asset Allocation Index (2000–2021)
This chart shows how Henan Taloph Pharmaceutical Stock Co Ltd's Strategic Asset Allocation Index has evolved across 22 annual periods from 2000 to 2021. As of September 2022, the index stands at 33.5%, representing strategic assets of CN¥538.86 Million against net assets of CN¥1.61 Billion CNY. Explore Henan Taloph Pharmaceutical Stock Co Ltd cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Henan Taloph Pharmaceutical Stock Co Ltd (2000–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Henan Taloph Pharmaceutical Stock Co Ltd from 2000 to 2021, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 600222 company net worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 30.4% | CN¥539.58 Million | CN¥539.58 Million | CN¥- | CN¥1.78 Billion | ▼ -1.9 pp |
| 2020 | 32.3% | CN¥494.09 Million | CN¥494.09 Million | CN¥- | CN¥1.53 Billion | ▼ -1.9 pp |
| 2019 | 34.2% | CN¥448.82 Million | CN¥448.82 Million | CN¥- | CN¥1.31 Billion | ▼ -10.5 pp |
| 2018 | 44.7% | CN¥621.73 Million | CN¥481.96 Million | CN¥139.77 Million | CN¥1.39 Billion | ▼ -4.0 pp |
| 2017 | 48.7% | CN¥734.76 Million | CN¥614.71 Million | CN¥120.05 Million | CN¥1.51 Billion | ▼ -6.6 pp |
| 2016 | 55.4% | CN¥830.43 Million | CN¥710.25 Million | CN¥120.18 Million | CN¥1.50 Billion | ▲ +2.6 pp |
| 2015 | 52.8% | CN¥791.63 Million | CN¥715.95 Million | CN¥75.68 Million | CN¥1.50 Billion | ▼ -3.2 pp |
| 2014 | 56.0% | CN¥664.55 Million | CN¥664.55 Million | CN¥- | CN¥1.19 Billion | ▼ -6.9 pp |
| 2013 | 62.9% | CN¥687.64 Million | CN¥687.64 Million | CN¥- | CN¥1.09 Billion | ▼ -44.8 pp |
| 2012 | 107.8% | CN¥707.60 Million | CN¥707.60 Million | CN¥- | CN¥656.50 Million | ▼ -4.2 pp |
| 2011 | 111.9% | CN¥704.04 Million | CN¥704.04 Million | CN¥- | CN¥628.89 Million | ▲ +12.5 pp |
| 2010 | 99.5% | CN¥606.24 Million | CN¥606.24 Million | CN¥- | CN¥609.32 Million | ▲ +3.9 pp |
| 2009 | 95.6% | CN¥560.45 Million | CN¥560.45 Million | CN¥- | CN¥586.04 Million | ▲ +5.0 pp |
| 2008 | 90.6% | CN¥502.89 Million | CN¥502.89 Million | CN¥- | CN¥554.97 Million | ▲ +9.1 pp |
| 2007 | 81.5% | CN¥425.32 Million | CN¥425.32 Million | CN¥- | CN¥521.57 Million | ▲ +6.5 pp |
| 2006 | 75.0% | CN¥365.48 Million | CN¥365.48 Million | CN¥- | CN¥487.05 Million | ▲ +1.9 pp |
| 2005 | 73.1% | CN¥345.00 Million | CN¥345.00 Million | CN¥- | CN¥471.96 Million | ▲ +7.5 pp |
| 2004 | 65.6% | CN¥298.76 Million | CN¥298.76 Million | CN¥- | CN¥455.68 Million | ▲ +2.4 pp |
| 2003 | 63.1% | CN¥278.12 Million | CN¥278.12 Million | CN¥- | CN¥440.61 Million | ▼ -1.5 pp |
| 2002 | 64.6% | CN¥276.69 Million | CN¥276.69 Million | CN¥- | CN¥428.30 Million | ▼ -1.8 pp |
| 2001 | 66.4% | CN¥276.73 Million | CN¥276.73 Million | CN¥- | CN¥416.84 Million | ▲ +10.9 pp |
| 2000 | 55.5% | CN¥227.63 Million | CN¥227.63 Million | CN¥- | CN¥410.41 Million | — |